Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II
Roche's development plans for a follow-on Avastin product have been called into question after the company noted briefly in its third-quarter earnings update that the drug failed in a Phase II study in colorectal cancer patients.
You may also be interested in...
Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer, but Bristol-Myers Squibb's Opdivo is pending for the same subgroup and Roche's Tecentriq could eventually gain a broader approval.
The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.